SRR2016940
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.490
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.470
- IL6_JAK_STAT3_SIGNALING+0.460
- INFLAMMATORY_RESPONSE+0.390
- COMPLEMENT+0.370
- HEDGEHOG_SIGNALING+0.370
- PANCREAS_BETA_CELLS+0.360
- COAGULATION+0.350
- ANGIOGENESIS+0.330
- TGF_BETA_SIGNALING+0.330
Top 10 suppressed
- E2F_TARGETS-0.500
- MYC_TARGETS_V2-0.500
- G2M_CHECKPOINT-0.440
- MYC_TARGETS_V1-0.420
- DNA_REPAIR-0.360
- UNFOLDED_PROTEIN_RESPONSE-0.300
- INTERFERON_ALPHA_RESPONSE-0.220
- MITOTIC_SPINDLE-0.160
- SPERMATOGENESIS-0.150
- OXIDATIVE_PHOSPHORYLATION-0.140
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-YC-A8S6-01A-31R-A38B-07 | — | — | 0.923 |
| 2 | X1ecc3a65.9882.4182.bb55.887a9bb9fc6a | — | cohortMD2 | 0.899 |
| 3 | BS_Z1A875MW | Glial-neuronal tumor NOS | — | 0.898 |
| 4 | SRR10899982 | — | — | 0.893 |
| 5 | TCGA-A2-A0EO-01A-11R-A034-07 | — | A | 0.892 |
| 6 | 88322 | EPN | Supratentorial EPN | 0.891 |
| 7 | TCGA-75-7030-01A-11R-1949-07 | — | cohortA1 | 0.889 |
| 8 | SRR12202494 | — | — | 0.889 |
| 9 | TCGA-56-A4ZJ-01A-11R-A262-07 | — | cohortSQ1 | 0.888 |
| 10 | SRR23303737 | — | — | 0.888 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.490 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.470 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.460 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.390 | Idelalisib | — uncovered |
| COMPLEMENT | 0.370 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.370 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.360 | Cobimetinib | — uncovered |
| COAGULATION | 0.350 | Binimetinib | — uncovered |
| ANGIOGENESIS | 0.330 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.330 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.320 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.320 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.320 | Inavolisib | — uncovered |
| HYPOXIA | 0.290 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.280 | Temsirolimus | — uncovered |
| UV_RESPONSE_DN | 0.280 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.260 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.240 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.220 | Inavolisib | — uncovered |
| APOPTOSIS | 0.210 | Idelalisib | — uncovered |